Clients | Pioneering & Emerging Technologies

Clients spearhead pioneering organizations and emerging technologies seeking to carve new paths in unchartered territory (internally or externally). In the face of an exciting wide range of future portfolio/partnership horizons, early phase decisions are often real-time, exploratory and opportunistic as teams assess new market landscapes. In building critical mass to the next level, leadership strives to optimize resources and harvest exploratory insight to streamline strategies in portfolio/pipeline planning and corporate business development (strategic partnerships, investments or divestitures).

Objectives range from mobilizing strategy & execution across partnerships, portfolio pipelines, optimizing runways, to building enterprise ecosystems for long-term growth, et al.

F&W | Creating Structure in Whitespace

F&W specializes in strategy and execution of critical mass builds for growth through strategic partnership ecosystems with comprehensive corporate development expertise (buy/sell-side) across the value chain from high-level enterprise strategy, portfolio/pipeline planning, search & evaluation/scouting, through to due diligence, transactions and alliance management.

With emphasis in pioneering and emerging technologies at the intersection of Pharmaceuticals/Biopharma and Medtech/TechBio/Device verticals , F&W brings insight to bridge and optimize cross-sector collaborations where there’s often potential for upside opportunities, risks, and momentum to get lost in translation, during rapid transformational inflections.

F&W empowers clients by aligning complex matrix teams along risk-managed strategies and streamlining processes to efficiently execute for growth in defining whitespaces - bringing a strong track record with leading multinationals’ pioneering cross-sector collaborations and initiatives:

• First non-invasive drug delivery for biologics programs (Device & Pharma)

• First Molecular Imaging/Theranostics programs (Nuclear Imaging, SaMD, Pharma)

• First Complementary diagnostic consortium for Malaria (Pharma & Diagnostics)

• First NGS companion diagnostic  in Immuno-oncology (Pharma & Medtech)

Leveraging both strategic & industry frontline operational know-how, F&W connects relevant dots in the big picture (eg. enterprise strategies/value propositions, market segments, targets/networks, etc) & in the weeds (eg. contract language, IP, market research/intelligence, process/teams)

F&W brings a mission and data-driven approach to Corporate Development & Strategy - in collaboration across Commercial/Marketing, R&D, Regulatory, Clinical Operations, Finance, Investor Relations, and Legal Domains (IP, contractual) - enabling clients to harness interdisciplinary subject matter expertise for optimal impact toward step-change value creation.

Learn More